News Releases

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced the appointments of Catherine Lee as senior vice

MET409 demonstrated notable improvements in decreased liver fat content and differentiated impacts on pruritus and LDL cholesterol after 12 weeks of treatment in NASH patients SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on discovering

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced that the U.S.

John McHutchison, AO, M.D., Appointed to Board of Directors Adding Significant Industry Experience and Drug Development Expertise SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class drugs to

- Randomized, placebo-controlled 12-week study showed mean liver fat reduction of up to 55% with MET409 - 93% of patients showed liver fat reduction of at least 30% from baseline SAN DIEGO, Jan. 22, 2020 /PRNewswire/ -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the

SAN DIEGO, October 15, 2019  – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Hubert Chen, M.D., Chief Medical Officer, will present at the H.C.

SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced it has entered into a loan and security agreement for up to $50

Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of

Promising signs of clinical efficacy without increase in LDL cholesterol SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will